ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF) ” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC).
These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com ). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org ) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov ). Printed copies of these documents are also available free of charge, by sending a postal request to the registered offices of ERYTECH Pharma, Bâtiment Adénine, 60 Avenue Rockefeller, 69008 in Lyon (France).
About ERYTECH: www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing erymethionase, methionine-γ-lyase encapsulated in red blood cells, to target cancer cells’ amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Director Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
+33 1 44 71 98 52
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
WELLS-FARGO16.10.2018 13:02 | pressemeddelelse
Wells Fargo Seeks Investment Firm License from the French Prudential Supervision and Resolution Authority (ACPR)
KOKUYO16.10.2018 12:15 | pressemeddelelse
KOKUYO to Showcase the Revolutionary "360° Gliding Chair ing" at ORGATEC 2018
BENTLEY-SYSTEMS16.10.2018 11:06 | pressemeddelelse
Going Digital (Twins): Bentley Inaugurates iTwin™ Services!
DIGITAL-ELEMENT16.10.2018 10:02 | pressemeddelelse
Clickadu Chooses Digital Element’s IP Intelligence Solution to Enable Accurate Geotargeting Globally
CA-UTIMACO16.10.2018 08:57 | pressemeddelelse
Utimaco Cleared to Complete Acquisition of Atalla
CA-PLAYGROUNDZ16.10.2018 08:54 | pressemeddelelse
PM Studios Partners with The Playgroundz Foundation to Develop New Blockchain Project
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum